# Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer

> **NCT00544765** · PHASE3 · COMPLETED · sponsor: **GBG Forschungs GmbH** · enrollment: 2014 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** TAC
- **DRUG:** NX

## Key facts

- **NCT ID:** NCT00544765
- **Lead sponsor:** GBG Forschungs GmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 2014 (ACTUAL)
- **Last updated:** 2021-02-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00544765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00544765, "Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00544765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*